ChiCTR2200055849 版本V1.2 版本创建时间2022/08/24 09:58:49 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200055849 

最近更新日期:

Date of Last Refreshed on:

2022-08-24 09:58:12 

注册时间:

Date of Registration:

2022-01-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

老年导尿管相关泌尿系感染回顾性临床研究

Public title:

Retrospective clinical research on urinary tract infection associated with catheter in the elderly patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

老年导尿管相关泌尿系感染回顾性临床研究

Scientific title:

Retrospective clinical research on urinary tract infection associated with catheter in the elderly patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙志宏 

研究负责人:

张桂芝 

Applicant:

Sun Zhihong 

Study leader:

Zhang Guizhi 

申请注册联系人电话:

Applicant telephone:

+86 15801469109

研究负责人电话:

Study leader's
telephone:

+86 18601048015

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

szh1790505@163.com

研究负责人电子邮件:

Study leader's E-mail:

zhanggz7769@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市复兴路28号

研究负责人通讯地址:

北京市复兴路28号

Applicant address:

28 Fuxing Road, Beijing, China

Study leader's address:

28 Fuxing Road, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100853

研究负责人邮政编码:

Study leader's postcode:

100853

申请人所在单位:

中国人民解放军总医院第二医学中心/国家老年临床研究中心呼吸与危重症医学科

Applicant's institution:

Department of Respiratory and Critical Care Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital

研究负责人所在单位:

中国人民解放军总医院第二医学中心/国家老年临床研究中心呼吸与危重症医学科

Affiliation of the Leader:

Department of Respiratory and Critical Care Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审第S2021-400-01号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军总医院医学伦理委员会

Name of the ethic committee:

Ethics Cpmmittee Of Chinese PLA General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-07-29 00:00:00

伦理委员会联系人:

曹江

Contact Name of the ethic committee:

Cao jiang

伦理委员会联系地址:

北京市复兴路28号,100853

Contact Address of the ethic committee:

No. 28 Fuxing Road, Beijing 100853, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军总医院第二医学中心

Primary sponsor:

The Second Medical Center , Chinese PLA General Hospital

研究实施负责(组长)单位地址:

北京市复兴路28号,100853

Primary sponsor's address:

No. 28 Fuxing Road, Beijing 100853, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院第二医学中心

具体地址:

复兴路28号

Institution
hospital:

The Second Medical Center, Chinese PLA General Hospital

Address:

28 Fuxing Road

经费或物资来源:

国家级科研课题

Source(s) of funding:

National Key research and development program

研究疾病:

老年导尿管相关泌尿系统感染  

Target disease:

urinary tract infection associated with catheter in the elderly patients

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

历史对照研究 

Study design:

Historical control 

研究目的:

①描述老年泌尿系感染的流行病学特征,包括临床特征、病原学特点、转归。 ②建立老年泌尿系感染的风险评估。  

Objectives of Study:

(1) describe the epidemiological characteristics of urinary tract infection in the elderly, including clinical features, etiological features and prognosis. ② To establish the risk assessment of urinary tract infection in the elderly.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合导尿管相关泌尿系感染患者诊断标准:
①留置尿管或拔除尿管后 48 h 内出现的尿路感染;对于尿道内、耻骨弓上或
间断留置导尿管的患者。符合 CAUTI 的临床症状和体征:包括新发的或逐渐加
重的发烧,寒战,意识改变,无其他明确原因的嗜睡;侧腹痛;肋脊角压痛;
急性血尿;盆腔部不适;在已经拔除导管的患者中还可能出现排尿困难,尿急
或尿频,或耻骨弓上疼痛或压痛。同时单次导管内或中段尿标本培养出至少 1
种细菌菌落数大于 103菌落形成单位(colony-forming units, cfu)/mL。无
症状 CAUTI 被定义为单次导管内尿标本培养出至少 1 种细菌菌落数大于 105
cfu/ml,同时无一般尿路感染的症状或体征。
②病历资料完整:包括一般情况、病史、实验室及影像学、病原学检查及病情
转归等。

Inclusion criteria

(1) meet the diagnostic criteria for patients with urinary tract infection related to urinary catheter:
① Urinary tract infection within 48 hours after indwelling or pulling out the urinary catheter; For patients with urethral catheter, pubic arch or intermittent indwelling catheter.
Clinical symptoms and signs consistent with CAUTI: including new or worsening fever, chills, change of consciousness and lethargy without other definite reasons; Lateral abdominal pain; Tenderness at the costal angle; Acute hematuria; Pelvic discomfort; Dysuria, urgency or frequent micturition, or pain or tenderness on the pubic arch may also occur in patients who have removed the catheter.
At the same time, at least one kind of bacteria with colony number greater than 103 colony-forming units (cfu)/mL was cultured from urine samples in a single catheter or middle section.
without Symptom CAUTI is defined as at least one bacterial colony with a number greater than 105cfu/ml cultured from a single catheter urine sample, and no symptoms or signs of general urinary tract infection.
② Complete medical records: including general situation, medical history, laboratory and imaging, etiological examination and disease outcome , etc

排除标准:

① 病历资料不完整的患者;
② 不符合导尿管相关尿路感染诊断标准的患者。

Exclusion criteria:

① Patients with incomplete medical records;
② Patients who do not meet the diagnostic criteria of urinary tract infection associated with catheter.

研究实施时间:

Study execute time:

From 2022-01-09 00:00:00 To 2023-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-09 00:00:00 To 2023-06-30 00:00:00

干预措施:

Interventions:

组别:

导尿管相关泌尿系感染患者

样本量:

470

Group:

patients with urinary tract infection related to urinary catheter

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院第二医学中心 

单位级别:

三级甲等 

Institution
hospital:

The Second Medical Center, Chinese PLA General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

尿常规

指标类型:

主要指标

Outcome:

Urine routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿培养

指标类型:

主要指标

Outcome:

Urine culture

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

降钙素原

指标类型:

次要指标

Outcome:

PCT

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Blood routine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血生化指标

指标类型:

次要指标

Outcome:

Blood biochemical index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

本研究为回顾性研究,不存在随机序列问题。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is retrospective, and there is no random sequence problem.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024.1.1 网络平台thttp://www.medresman.org/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2024.1.1 available at http://www.medresman.org/login.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集使用病例记录表(Case Record Form, CRF),电子采集和管理系统(Electronic Data Capture, EDC)使用ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

use CRF and ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-01-20 17:13:58